A single blind, comparative, multicentre, randomized study of the efficacy and safety of Pegstim, solution for subcutaneous injection, 6 mg/0.6 mL (Cadila Healthcare Ltd., India), and Neulastim, solution for subcutaneous injection, 6 mg/0.6 mL (Amgen Manufacturing Limited, USA), in patients diagnosed with breast cancer who receive myelosuppressive chemotherapy.
Phase of Trial: Phase III
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Rus Biopharm
- 26 Mar 2018 Status changed from not yet recruiting to completed.
- 11 Apr 2017 New trial record